TheraRadar
Data updated: Jun 28, 2026

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER (cefepime hydrochloride) · B BRAUN

Infectious Disease Approved 2010-05-06

Cefepime and Dextrose is a cephalosporin antibacterial indicated for the treatment of moderate to severe pneumonia, uncomplicated and complicated urinary tract infections (including pyelonephritis), and uncomplicated skin and skin structure infections caused by susceptible isolates. It is also indicated as empiric monotherapy for febrile neutropenic patients and for use in combination with metronidazole for the treatment of complicated intra-abdominal infections. To maintain antimicrobial stewardship and reduce the development of drug-resistant bacteria, this medication should be reserved for infections proven or strongly suspected to be caused by susceptible microorganisms.

How CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER Works

Cefepime is a fourth-generation cephalosporin that exerts bactericidal activity by inhibiting bacterial cell wall synthesis. It binds to one or more of the penicillin-binding proteins (PBPs), which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls. This disruption leads to bacterial cell wall instability and subsequent osmotic lysis. It possesses a broad spectrum of activity against various Gram-positive and Gram-negative bacteria, including *Pseudomonas aeruginosa* and *Streptococcus pneumoniae*.

NDA
Small Molecule
1
Indication
--
Phase 3 Trials
16
Years on Market

Details

Status
Prescription
First Approved
2010-05-06
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: CEFEPIME HYDROCHLORIDE

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER Approval History

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
12 FDA actions from 2010 to 2026
Apr 2026 SUPPL
Label · Labeling
Mar 2022 SUPPL
Label · Labeling
Nov 2015 SUPPL
Label · Labeling

What CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER Treats

6 indications

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER is approved for 6 conditions since its original approval in 2010. These indications span multiple therapeutic areas including oncology, immunology, and more.

Source: FDA Label

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AZACTAM
AZTREONAM
4 shared
LABS DELBERT
AZTREONAM
AZTREONAM
4 shared
Pfizer
CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE
4 shared
QILU ANTIBIOTICS
Shared indications:
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT01484015 IRB00015247 NCI-2011-02422, CCCWFU 02110 Ph 1 completed Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER FDA Label Details

Indications & Usage

FDA Label (PDF)

Cefepime for Injection and Dextrose Injection is a cephalosporin antibacterial indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia Empiric therapy for febrile neutropenic patients Uncomplicated and complicated urinary tract infections Uncomplicated skin and skin structure infections Complicated intra-abdominal infections (used in combination with metronidazole) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and Dextrose Injection and other antibacterial dr...

Track CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.